COFCO Biotechnology Balance Sheet Health
Financial Health criteria checks 5/6
COFCO Biotechnology has a total shareholder equity of CN¥10.9B and total debt of CN¥3.9B, which brings its debt-to-equity ratio to 35.4%. Its total assets and total liabilities are CN¥17.2B and CN¥6.3B respectively.
Key information
35.4%
Debt to equity ratio
CN¥3.86b
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥1.67b |
| Equity | CN¥10.90b |
| Total liabilities | CN¥6.28b |
| Total assets | CN¥17.18b |
Recent financial health updates
We Think COFCO Biotechnology (SZSE:000930) Has A Fair Chunk Of Debt
Sep 30
COFCO Biotechnology (SZSE:000930) Is Carrying A Fair Bit Of Debt
Jun 03Recent updates
COFCO Biotechnology Co., Ltd. (SZSE:000930) Surges 39% Yet Its Low P/S Is No Reason For Excitement
Oct 14We Think COFCO Biotechnology (SZSE:000930) Has A Fair Chunk Of Debt
Sep 30COFCO Biotechnology Co., Ltd. (SZSE:000930) Looks Inexpensive But Perhaps Not Attractive Enough
Jul 17COFCO Biotechnology (SZSE:000930) Is Carrying A Fair Bit Of Debt
Jun 03Returns On Capital Signal Tricky Times Ahead For COFCO Biotechnology (SZSE:000930)
Apr 17COFCO Biotechnology Co., Ltd.'s (SZSE:000930) Price Is Right But Growth Is Lacking
Mar 07Financial Position Analysis
Short Term Liabilities: 000930's short term assets (CN¥6.8B) exceed its short term liabilities (CN¥5.7B).
Long Term Liabilities: 000930's short term assets (CN¥6.8B) exceed its long term liabilities (CN¥618.2M).
Debt to Equity History and Analysis
Debt Level: 000930's net debt to equity ratio (20.1%) is considered satisfactory.
Reducing Debt: 000930's debt to equity ratio has reduced from 49.6% to 35.4% over the past 5 years.
Debt Coverage: 000930's debt is well covered by operating cash flow (20.5%).
Interest Coverage: Insufficient data to determine if 000930's interest payments on its debt are well covered by EBIT.